Extract
Acute respiratory distress syndrome (ARDS) is a clinical syndrome of severe acute hypoxaemic respiratory failure with clinical features including reduced lung compliance and permeability-induced pulmonary oedema, which can frequently progress to multiple organ failure [1, 2]. ARDS occurs in 10% of all critically patients in ICU and nearly one quarter of all mechanically ventilated patients [3]. Common underlying causes of ARDS include bacterial or viral pneumonia, sepsis, pulmonary aspiration and trauma [4]. The burden of ARDS is substantial, with hospital mortality rates varying, depending on ARDS severity, from 30–45% of affected patients [5]. Of further concern, ARDS survivors are often left with debilitating long-term sequelae which reduces their quality of life.
Abstract
An enhanced understanding of the impact of the lung microenvironment on exogenously administered mesenchymal stromal cells has the potential to enhance their therapeutic potential for ARDShttps://bit.ly/2S2fQ1I
Footnotes
Conflict of interest: C. Masterson has nothing to disclose.
Conflict of interest: H. Gonzalez has nothing to disclose.
Conflict of interest: J.G. Laffey reports grants/contracts from Science Foundation Ireland and Health Research Board; consulting fees from Baxter Healthcare and GlaxoSmithKline; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Baxter Healthcare; and was a participant on a data safety monitoring board for a stem cell trial in COVID-19 in Toronto.
- ReceivedApril 3, 2021.
- AcceptedApril 24, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contactpermissions{at}ersnet.org